B-intervention	0	11	Anastrozole
O	12	18	versus
B-control	19	28	tamoxifen
O	29	32	for
O	33	36	the
O	37	47	prevention
O	48	50	of
O	51	63	locoregional
O	64	67	and
O	68	81	contralateral
O	82	88	breast
O	89	95	cancer
O	96	98	in
O	99	113	postmenopausal
O	114	119	women
O	120	124	with
O	125	132	locally
O	133	140	excised
O	141	147	ductal
O	148	157	carcinoma
O	158	160	in
O	161	165	situ
O	166	167	(
O	167	171	IBIS
O	171	172	-
O	172	174	II
O	175	179	DCIS
O	179	180	)
O	180	181	:
O	182	183	a
O	184	190	double
O	190	191	-
O	191	196	blind
O	196	197	,
O	198	208	randomised
O	209	219	controlled
O	220	225	trial
O	225	226	.

O	227	232	Third
O	232	233	-
O	233	243	generation
O	244	253	aromatase
O	254	264	inhibitors
O	265	268	are
O	269	273	more
O	274	283	effective
O	284	288	than
O	289	298	tamoxifen
O	299	302	for
O	303	313	preventing
O	314	324	recurrence
O	325	327	in
O	328	342	postmenopausal
O	343	348	women
O	349	353	with
O	354	361	hormone
O	361	362	-
O	362	370	receptor
O	370	371	-
O	371	379	positive
O	380	388	invasive
O	389	395	breast
O	396	402	cancer
O	402	403	.

O	404	411	However
O	411	412	,
O	413	415	it
O	416	418	is
O	419	422	not
O	423	428	known
O	429	436	whether
O	437	448	anastrozole
O	449	451	is
O	452	456	more
O	457	466	effective
O	467	471	than
O	472	481	tamoxifen
O	482	485	for
O	486	491	women
O	492	496	with
O	497	504	hormone
O	504	505	-
O	505	513	receptor
O	513	514	-
O	514	522	positive
O	523	529	ductal
O	530	539	carcinoma
O	540	542	in
O	543	547	situ
O	548	549	(
O	549	553	DCIS
O	553	554	)
O	554	555	.

O	556	560	Here
O	560	561	,
O	562	564	we
O	565	572	compare
O	573	576	the
O	577	585	efficacy
O	586	588	of
O	589	600	anastrozole
O	601	605	with
O	606	610	that
O	611	613	of
O	614	623	tamoxifen
O	624	626	in
O	627	641	postmenopausal
O	642	647	women
O	648	652	with
O	653	660	hormone
O	660	661	-
O	661	669	receptor
O	669	670	-
O	670	678	positive
O	679	683	DCIS
O	683	684	.

O	685	687	In
O	688	689	a
O	690	696	double
O	696	697	-
O	697	702	blind
O	702	703	,
O	704	715	multicentre
O	715	716	,
O	717	727	randomised
O	728	735	placebo
O	735	736	-
O	736	746	controlled
O	747	752	trial
O	752	753	,
O	754	756	we
O	757	766	recruited
B-eligibility	767	772	women
I-eligibility	773	776	who
I-eligibility	777	780	had
I-eligibility	781	785	been
I-eligibility	786	795	diagnosed
I-eligibility	796	800	with
I-eligibility	801	808	locally
I-eligibility	809	816	excised
I-eligibility	816	817	,
I-eligibility	818	825	hormone
I-eligibility	825	826	-
I-eligibility	826	834	receptor
I-eligibility	834	835	-
I-eligibility	835	843	positive
I-eligibility	844	848	DCIS
O	848	849	.

O	850	858	Eligible
O	859	864	women
O	865	869	were
O	870	878	randomly
O	879	887	assigned
O	888	890	in
O	891	892	a
O	893	894	1
O	894	895	:
O	895	896	1
O	897	902	ratio
O	903	905	by
O	906	913	central
O	914	922	computer
O	923	933	allocation
O	934	936	to
O	937	944	receive
O	945	946	1
O	947	949	mg
O	950	954	oral
O	955	966	anastrozole
O	967	969	or
O	970	972	20
O	973	975	mg
O	976	980	oral
O	981	990	tamoxifen
O	991	996	every
O	997	1000	day
O	1001	1004	for
O	1005	1006	5
O	1007	1012	years
O	1012	1013	.

O	1014	1027	Randomisation
O	1028	1031	was
O	1032	1042	stratified
O	1043	1045	by
O	1046	1051	major
O	1052	1058	centre
O	1059	1061	or
O	1062	1065	hub
O	1066	1069	and
O	1070	1073	was
O	1074	1078	done
O	1079	1081	in
O	1082	1088	blocks
O	1089	1090	(
O	1090	1093	six
O	1093	1094	,
O	1095	1100	eight
O	1100	1101	,
O	1102	1104	or
O	1105	1108	ten
O	1108	1109	)
O	1109	1110	.

O	1111	1114	All
O	1115	1120	trial
O	1121	1130	personnel
O	1130	1131	,
O	1132	1144	participants
O	1144	1145	,
O	1146	1149	and
O	1150	1160	clinicians
O	1161	1165	were
O	1166	1172	masked
O	1173	1175	to
O	1176	1185	treatment
O	1186	1196	allocation
O	1197	1200	and
O	1201	1205	only
O	1206	1209	the
O	1210	1215	trial
O	1216	1228	statistician
O	1229	1232	had
O	1233	1239	access
O	1240	1242	to
O	1243	1252	treatment
O	1253	1263	allocation
O	1263	1264	.

O	1265	1268	The
O	1269	1276	primary
O	1277	1285	endpoint
O	1286	1289	was
B-outcome-Measure	1290	1293	all
I-outcome-Measure	1294	1304	recurrence
O	1304	1305	,
O	1306	1315	including
O	1316	1325	recurrent
O	1326	1330	DCIS
O	1331	1334	and
O	1335	1338	new
O	1339	1352	contralateral
O	1353	1360	tumours
O	1360	1361	.

O	1362	1365	All
O	1366	1374	analyses
O	1375	1379	were
O	1380	1384	done
O	1385	1387	on
O	1388	1389	a
O	1390	1398	modified
O	1399	1408	intention
O	1408	1409	-
O	1409	1411	to
O	1411	1412	-
O	1412	1417	treat
O	1418	1423	basis
O	1424	1425	(
O	1425	1427	in
O	1428	1431	all
O	1432	1437	women
O	1438	1441	who
O	1442	1446	were
O	1447	1457	randomised
O	1458	1461	and
O	1462	1465	did
O	1466	1469	not
O	1470	1476	revoke
O	1477	1484	consent
O	1485	1488	for
O	1489	1494	their
O	1495	1499	data
O	1500	1502	to
O	1503	1505	be
O	1506	1514	included
O	1514	1515	)
O	1516	1519	and
O	1520	1532	proportional
O	1533	1539	hazard
O	1540	1546	models
O	1547	1551	were
O	1552	1556	used
O	1557	1559	to
O	1560	1567	compute
O	1568	1574	hazard
O	1575	1581	ratios
O	1582	1585	and
O	1586	1599	corresponding
O	1600	1610	confidence
O	1611	1620	intervals
O	1620	1621	.

O	1622	1626	This
O	1627	1632	trial
O	1633	1635	is
O	1636	1646	registered
O	1647	1649	at
O	1650	1653	the
O	1654	1660	ISRCTN
O	1661	1669	registry
O	1669	1670	,
O	1671	1677	number
O	1678	1692	ISRCTN37546358
O	1692	1693	.

O	1694	1701	Between
O	1702	1707	March
O	1708	1709	3
O	1709	1710	,
O	1711	1715	2003
O	1715	1716	,
O	1717	1720	and
O	1721	1724	Feb
O	1725	1726	8
O	1726	1727	,
O	1728	1732	2012
O	1732	1733	,
O	1734	1736	we
O	1737	1745	enrolled
B-total-participants	1746	1750	2980
O	1751	1765	postmenopausal
O	1766	1771	women
O	1772	1776	from
O	1777	1780	236
O	1781	1788	centres
O	1789	1791	in
O	1792	1794	14
O	1795	1804	countries
O	1805	1808	and
O	1809	1817	randomly
O	1818	1826	assigned
O	1827	1831	them
O	1832	1834	to
O	1835	1842	receive
O	1843	1854	anastrozole
O	1855	1856	(
B-intervention-participants	1856	1860	1449
O	1861	1869	analysed
O	1869	1870	)
O	1871	1873	or
O	1874	1883	tamoxifen
O	1884	1885	(
B-control-participants	1885	1889	1489
O	1890	1898	analysed
O	1898	1899	)
O	1899	1900	.

O	1901	1907	Median
O	1908	1914	follow
O	1914	1915	-
O	1915	1917	up
O	1918	1921	was
O	1922	1923	7
O	1923	1924	·
O	1924	1925	2
O	1926	1931	years
O	1932	1933	(
O	1933	1936	IQR
O	1937	1938	5
O	1938	1939	·
O	1939	1940	6
O	1940	1941	-
O	1941	1942	8
O	1942	1943	·
O	1943	1944	9
O	1944	1945	)
O	1945	1946	,
O	1947	1950	and
O	1951	1954	144
B-outcome	1955	1961	breast
I-outcome	1962	1968	cancer
I-outcome	1969	1980	recurrences
O	1981	1985	were
O	1986	1994	recorded
O	1994	1995	.

O	1996	1998	We
O	1999	2004	noted
O	2005	2007	no
O	2008	2021	statistically
O	2022	2033	significant
O	2034	2044	difference
O	2045	2047	in
B-outcome	2048	2055	overall
I-outcome	2056	2066	recurrence
O	2067	2068	(
B-iv-bin-abs	2068	2070	67
O	2071	2082	recurrences
O	2083	2086	for
O	2087	2098	anastrozole
O	2099	2101	vs
B-cv-bin-abs	2102	2104	77
O	2105	2108	for
O	2109	2118	tamoxifen
O	2118	2119	;
O	2120	2122	HR
O	2123	2124	0
O	2124	2125	·
O	2125	2127	89
O	2128	2129	[
O	2129	2131	95
O	2131	2132	%
O	2133	2135	CI
O	2136	2137	0
O	2137	2138	·
O	2138	2140	64
O	2140	2141	-
O	2141	2142	1
O	2142	2143	·
O	2143	2145	23
O	2145	2146	]
O	2146	2147	)
O	2147	2148	.

O	2149	2152	The
O	2153	2156	non
O	2156	2157	-
O	2157	2168	inferiority
O	2169	2171	of
O	2172	2183	anastrozole
O	2184	2187	was
O	2188	2199	established
O	2200	2201	(
O	2201	2206	upper
O	2207	2209	95
O	2209	2210	%
O	2211	2213	CI
O	2214	2215	<
O	2215	2216	1
O	2216	2217	·
O	2217	2219	25
O	2219	2220	)
O	2220	2221	,
O	2222	2225	but
O	2226	2229	its
O	2230	2241	superiority
O	2242	2244	to
O	2245	2254	tamoxifen
O	2255	2258	was
O	2259	2262	not
O	2263	2264	(
O	2264	2265	p
O	2265	2266	=
O	2266	2267	0
O	2267	2268	·
O	2268	2270	49
O	2270	2271	)
O	2271	2272	.

O	2273	2274	A
O	2275	2280	total
O	2281	2283	of
O	2284	2286	69
B-outcome	2287	2293	deaths
O	2294	2298	were
O	2299	2307	recorded
O	2308	2309	(
B-iv-bin-abs	2309	2311	33
O	2312	2315	for
O	2316	2327	anastrozole
O	2328	2330	vs
B-cv-bin-abs	2331	2333	36
O	2334	2337	for
O	2338	2347	tamoxifen
O	2347	2348	;
O	2349	2351	HR
O	2352	2353	0
O	2353	2354	·
O	2354	2356	93
O	2357	2358	[
O	2358	2360	95
O	2360	2361	%
O	2362	2364	CI
O	2365	2366	0
O	2366	2367	·
O	2367	2369	58
O	2369	2370	-
O	2370	2371	1
O	2371	2372	·
O	2372	2374	50
O	2374	2375	]
O	2375	2376	,
O	2377	2378	p
O	2378	2379	=
O	2379	2380	0
O	2380	2381	·
O	2381	2383	78
O	2383	2384	)
O	2384	2385	,
O	2386	2389	and
O	2390	2392	no
O	2393	2401	specific
O	2402	2407	cause
O	2408	2411	was
O	2412	2416	more
O	2417	2423	common
O	2424	2426	in
O	2427	2430	one
O	2431	2436	group
O	2437	2441	than
O	2442	2445	the
O	2446	2451	other
O	2451	2452	.

O	2453	2456	The
O	2457	2463	number
O	2464	2466	of
O	2467	2472	women
O	2473	2482	reporting
O	2483	2486	any
B-outcome	2487	2494	adverse
I-outcome	2495	2500	event
O	2501	2504	was
O	2505	2512	similar
O	2513	2520	between
O	2521	2532	anastrozole
O	2533	2534	(
B-iv-bin-abs	2534	2538	1323
O	2539	2544	women
O	2544	2545	,
B-iv-bin-percent	2546	2548	91
I-iv-bin-percent	2548	2549	%
O	2549	2550	)
O	2551	2554	and
O	2555	2564	tamoxifen
O	2565	2566	(
B-cv-bin-abs	2566	2570	1379
O	2571	2576	women
O	2576	2577	,
B-cv-bin-percent	2578	2580	93
I-cv-bin-percent	2580	2581	%
O	2581	2582	)
O	2582	2583	;
O	2584	2587	the
O	2588	2592	side
O	2592	2593	-
O	2593	2599	effect
O	2600	2608	profiles
O	2609	2611	of
O	2612	2615	the
O	2616	2619	two
O	2620	2625	drugs
O	2626	2634	differed
O	2634	2635	,
O	2636	2640	with
O	2641	2645	more
B-outcome	2646	2655	fractures
O	2655	2656	,
B-outcome	2657	2672	musculoskeletal
I-outcome	2673	2679	events
O	2679	2680	,
B-outcome	2681	2702	hypercholesterolaemia
O	2702	2703	,
O	2704	2707	and
B-outcome	2708	2715	strokes
O	2716	2720	with
O	2721	2732	anastrozole
O	2733	2736	and
O	2737	2741	more
B-outcome	2742	2748	muscle
I-outcome	2749	2754	spasm
O	2754	2755	,
B-outcome	2756	2770	gynaecological
I-outcome	2771	2778	cancers
I-outcome	2779	2782	and
I-outcome	2783	2791	symptoms
O	2791	2792	,
B-outcome	2793	2802	vasomotor
I-outcome	2803	2811	symptoms
O	2811	2812	,
O	2813	2816	and
B-outcome	2817	2821	deep
I-outcome	2822	2826	vein
I-outcome	2827	2837	thromboses
O	2838	2842	with
O	2843	2852	tamoxifen
O	2852	2853	.

O	2854	2856	No
O	2857	2862	clear
B-outcome	2863	2871	efficacy
O	2872	2883	differences
O	2884	2888	were
O	2889	2893	seen
O	2894	2901	between
O	2902	2905	the
O	2906	2909	two
O	2910	2920	treatments
O	2920	2921	.

O	2922	2933	Anastrozole
O	2934	2940	offers
O	2941	2948	another
O	2949	2958	treatment
O	2959	2965	option
O	2966	2969	for
O	2970	2984	postmenopausal
O	2985	2990	women
O	2991	2995	with
O	2996	3003	hormone
O	3003	3004	-
O	3004	3012	receptor
O	3012	3013	-
O	3013	3021	positive
O	3022	3026	DCIS
O	3026	3027	,
O	3028	3033	which
O	3034	3037	may
O	3038	3040	be
O	3041	3043	be
O	3044	3048	more
O	3049	3060	appropriate
O	3061	3064	for
O	3065	3069	some
O	3070	3075	women
O	3076	3080	with
O	3081	3098	contraindications
O	3099	3102	for
O	3103	3112	tamoxifen
O	3112	3113	.

O	3114	3120	Longer
O	3121	3127	follow
O	3127	3128	-
O	3128	3130	up
O	3131	3135	will
O	3136	3138	be
O	3139	3148	necessary
O	3149	3151	to
O	3152	3157	fully
O	3158	3166	evaluate
O	3167	3176	treatment
O	3177	3188	differences
O	3188	3189	.

O	3190	3196	Cancer
O	3197	3205	Research
O	3206	3208	UK
O	3208	3209	,
O	3210	3218	National
O	3219	3225	Health
O	3226	3229	and
O	3230	3237	Medical
O	3238	3246	Research
O	3247	3254	Council
O	3255	3264	Australia
O	3264	3265	,
O	3266	3272	Breast
O	3273	3279	Cancer
O	3280	3288	Research
O	3289	3293	Fund
O	3293	3294	,
O	3295	3306	AstraZeneca
O	3306	3307	,
O	3308	3314	Sanofi
O	3315	3322	Aventis
O	3322	3323	.
